OAC
ORKA

OMERS Administration Corp’s Oruka Therapeutics ORKA Stock Holding History

OMERS Administration Corp’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,900
Closed -$461K – 1132
2025
Q1 		$461K Buy
44,900
+25,100
+127% +$313K ﹤0.01% 753
2024
Q4 		$384K Buy
+19,800
New +$483K ﹤0.01% 760

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OMERS Administration Corp's ORKA Position: Q2 2025 in Review

OMERS Administration Corp sold out of Oruka Therapeutics (ORKA) in Q2 2025, closing a stake of 44,900 shares — an estimated $461K sold.

OMERS Administration Corp first reported a position in ORKA in Q4 2024 and held it in 2 quarters. The position peaked at $461K in Q1 2025. 81 funds tracked by Wall St. Rank hold ORKA as of Q2 2025.

  • OMERS Administration Corp reported no remaining Oruka Therapeutics position as of Q2 2025 after selling out during the quarter.
  • OMERS Administration Corp sold 44,900 Oruka Therapeutics shares in Q2 2025, an estimated $461K.
  • OMERS Administration Corp first reported a position in Oruka Therapeutics in Q4 2024 and held it in 2 quarters.
  • OMERS Administration Corp's Oruka Therapeutics position peaked at $461K in Q1 2025.
  • 81 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2025.

Based on OMERS Administration Corp's 13F filing for Q2 2025, filed 13 Aug 2025.